Blastic plasmacytoid DC (BPDC) neoplasms are rare CD56 þ /CD4 þ -positive tumours derived from the precursors of plasmacytoid DCs. They were formerly known as blastic NK-cell lymphoma or agranular CD4 þ /CD56 þ haematodermic tumours. 1, 2 Clinically, the disease initially presents with asymptomatic skin lesions, often associated with BM involvement. The clinical course is usually aggressive with a median survival of 12-14 months. 3, 4 Relapses after chemotherapy are frequent and patients mostly succumb to overt leukaemia. 5 Long-lasting remissions are sporadic and have been reported in young patients after treatment with chemotherapy regimens appropriate for leukaemia followed by allogeneic SCT. 1, 3 We report the case of a patient after allogeneic SCT, for whom immunologic tumour surveillance by the allograft was achieved, but who developed fulminant leukaemia progression during extracorporeal photopheresis (ECP).
A 32-year-old male presented to our clinic in November 2003 with a cutaneous nodule of 6 Â 4 cm on the right upper arm, histologically recognised as a CD4 þ /CD56 þ blastic neoplasm of the cutis. Beside CD4 þ /CD56 þ , these cells were positive for CD2 ( þ ), CD7, CD45, strongly for CD38 þþ and expressed granzyme B. No expression of CD3-, CD8-, CD5-, CD30-, CD57-, LMP-, CD10-or CD1a-was detected. Proliferation rate (Ki-67 positive) was 40-50%. There was no evidence of nodal or further extranodal involvement. Six cycles CHOEP-14 chemotherapy followed by 36 Gy involved field radiation induced complete disease remission. At 11 months after the start of initial therapy a multifocal, slowly progressing cutaneous relapse occurred, verified by histology. Salvage therapy comprised four cycles of ifosfamide, carboplatin and etoposide chemotherapy (October to December 2005) and 36 Gy radiation of residual cutaneous manifestations. The second relapse occurred within 3 months and four cycles of salvage chemotherapy with fludarabine and cyclophosphamide (March to June 2006) induced a further remission. In August 2006, consolidating allogeneic SCT was performed from a fully matched unrelated donor after dose-reduced conditioning chemotherapy with fludarabine, busulfan and cyclophosphamide. The patient experienced acute cutaneous GVHD grade IV with desquamation and formation of bullae necessitating prolonged use of steroids.
In March 2007 and October 2007 further cutaneous relapses occurred, both histologically proven. CD123 was analyzed this time and strongly expressed; MPO-, CD79a-, and CD8-negativity, with TdT could not be analyzed for technical reasons. Relapses were treated with local irradiation. Intraoral and ocular GVHD were treated with tacrolimus and systemic steroids at low doses. In February 2008 signs of pulmonary GVHD developed, so that in addition to tacrolimus and both inhaled and systemic steroids ECP was started in July 2008. This allowed steroids to be tapered to 7.5 mg prednisolone.
After 12 months with no evidence of the tumour and after the seventh cycle of ECP, GVHD was controlled. However, in January 2009 a new cutaneous relapse occurred, this time associated with nearly complete BM infiltration by CD4 þ / CD56 þ blastic plasmacytoid dendritic tumour cells. His deteriorating general condition did not allow further salvage therapy and the patient died 66 months after initial diagnosis and 8 months after onset of ECP.
Prognosis for patients with blastic plasmacytoid DC neoplasms is poor. Although CRs can be induced with CHOP-like chemotherapy regimens, early relapses with rapid fatal outcome are frequent. 5 In the index patient, CHOEP chemotherapy with consecutive local irradiation led to a complete remission for 11 months. In all, 36% of patients with BPDC-as well as our patient-show no signs of systemic disease at the start of therapy. 6 However extranodal lymphoid organs such as liver, spleen, mucosa including the nasopharynx and bronchi as well as the BM may be infiltrated. Because of the often leukaemic disease course, acute leukaemia regimens are now recommended therapy of BPDC. 6 New treatment strategies are urgently needed for these poor prognosis patients. Novel antifolate agents such as pralaxate are under investigation, 7 and because of their origin, 2 tyrosine kinase inhibitors targeting flt-3 should be evaluated. At this point in time, however, therapeutic interventions remain challenging for BPDC. Data about allogeneic SCT are still scarce, but long term remissions have been reported in rare cases. 5 In the index patient, chronic GVHD occurred after allogenic SCT, but the tumour was controlled for more than 28 months by a presumed GVL effect and radiotherapy. GVHD is a common and often serious complication affecting more than 30% of patients after allogeneic SCT. ECP is effective both in chronic GVHD 8 and in cutaneous T-cell lymphoma, 9 so this procedure was started. At 8 months after initiation of ECP, however, the index patient experienced rapid disease progression.
The mechanism of action of ECP is not entirely understood, but it is postulated that 8-methoxypsoralen activated by UV light covalently binds and crosslinks DNA, leading to initiation of apoptosis in about 80% of the phototreated lymphocytes. A promotion of monocytic differentiation towards active APCs has been reported, as well as strong stimulation of monocytes to produce increasing amounts of cytokines. 10 ECP stimulates the transition of normal monocytes to immature cyCD83 þ , CD36 þ DCs 11 with these markers also being expressed on BPDC.
12 Does ECP therefore boost tumour progression in this rare disease?
This report emphasises the relevance of immunologic tumour-surveillance after allogeneic SCT which seems to be associated with GVHD. Although the sequence of ECP and disease progression may have happened by mere chance in our patient, the selection of ECP for the treatment of GVHD should be evaluated carefully in patients with blastic plasmacytoid DC neoplasms to avoid malignant cell stimulation.
